Business
PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export
PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivat...
About this update from Pharmacielo Ltd.
[{"type":"text","content":"\n\n\n\nPharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and RIONEGRO, Colombia, July 8, 2020\n\n\n\nEnables PharmaCielo to produce and deliver psychoactive extracts as part of the three-year extracts agreement the Company announced in January of this year, intended for the German market Enhances product development flexibility and will accelerate PharmaCielo's strategic priority to expand beyond CBD oils and isolates to meet market demand TORONTO and RIONEGRO, Colombia, July 8, 2020 /CNW/ - PharmaCielo Ltd. (\"PharmaCielo\" or the \"Company\") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that the Colombian government granted the Company authorization for the 2020 commercial cultivation, production and export of high-THC medicinal cannabis extracts, in fulfilment of existing sales agreements.  \n\n \n \n \n \n \n \n\n \nThe commercial quotas obtained from the ministries of Justice and Health, enable the Company to immediately begin cultivation and processing of 10 tonnes of THC-dominant dry flower.   \n\"The government's approval for PharmaCielo to grow, extract and export high-THC medicinal products is a significant milestone that significantly expands our product portfolio and complements our medicinal offerings of CBD oil and isolate,\" says David Attard, CEO. \"This THC quota, coupled with expanded processing and extraction capacity, enables greater flexibility for us to fulfill current international customer obligations as well as to engage the B2B market with a broader product offering range at scale.\" \nHenning von Koss, President of PharmaCielo Ltd., added, \"The truly successful medicinal use of cannabis depends to a great extent on managing its psychoactive and non-psychoactive properties. A broad portfolio is important, but even more important ...